4.5 Article

Time Trends in Opioid Use Disorder Hospitalizations in Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, and Low Back Pain

Journal

JOURNAL OF RHEUMATOLOGY
Volume 48, Issue 5, Pages 775-784

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.191370

Keywords

opioid use disorder; healthcare utilization; outcomes; time trends; rheumatic diseases; musculoskeletal diseases

Categories

Funding

  1. Division of Rheumatology at the University of Alabama at Birmingham

Ask authors/readers for more resources

In this study, opioid use disorder (OUD)-related hospitalizations and healthcare utilization outcomes were examined in people with 5 common musculoskeletal diseases, including gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain. The results showed an increase in OUD hospitalizations across all 5 diseases, with varying rates of increase. Additionally, differences in hospital charges and length of stay were observed among the different musculoskeletal diseases.
Objective. To examine opioid use disorder (OUD)-related hospitalizations and associated healthcare utilization outcomes in people with 5 common musculoskeletal diseases (MSD). Methods. We used the US National Inpatient Sample (NIS) data from 1998 to 2014 to examine the rates of OUD hospitalizations (per 100,000 NIS claims overall), time trends, and outcomes in 5 common rheumatic diseases: gout, rheumatoid arthritis (RA), fibromyalgia (FM), osteoarthritis (OA), and low back pain (LBP). Results. OUD hospitalization rate per 100,000 total NIS claims in 1998-2000 vs 2015-2016 (and increase) were as follows: gout, 0.05 vs 1.88 (36-fold); OA, 0.68 vs 10.22 (14-fold); FM, 0.53 vs 6.98 (12-fold); RA, 0.30 vs 3.16 (9.5-fold); and LBP, 1.17 vs 7.64 (5.5-fold). The median hospital charges and hospital stays for OUD hospitalizations were as follows: gout, $18,363 and 2.5 days; RA, $17,398 and 2.4 days; FM, $15,772 and 2.1 days; OA, $16,795 and 2.4 days; and LBP, $13,722 and 2.0 days. In-hospital mortality rates ranged from 0.9% for LBP and FM to 1.7% for gout with OUD hospitalizations. Compared to those without each MSD, age-, sex-, race-, and income-adjusted total hospital charges (inflation-adjusted) for OUD hospitalizations with each rheumatic disease were as follows: gout, $697 higher; OA, $4759 lower; FM, $2082 lower; RA, $1258 lower; and I.BP, $4944 lower. Conclusion. OUD hospitalizations increased in all 5 MSD studied, but the rate of increase differed. Awareness of these OUD hospitalization trends in 5 MSD among providers, policy makers, and patients is important. Development and implementation of interventions, policies, and practices to potentially reduce OUD-associated effects in people with rheumatic diseases is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Policy & Services

Organizational context and the learning and change readiness climate for implementing an evidence-based shared decision-making aid in US rheumatology clinics

Larry Hearld, Allyson Hall, Reena Joseph Kelly, Aizhan Karabukayeva, Jasvinder Singh

Summary: The study found that most clinics reported strong positive learning and change readiness climates, but more complex organizations and members with longer tenure may have less supportive learning and change readiness climates.

JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT (2022)

Article Peripheral Vascular Disease

Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension

Brittany Butts, Jamelle A. Brown, Thomas S. Denney, Scott Ballinger, Steven G. Lloyd, Suzanne Oparil, Paul Sanders, Tony R. Merriman, Angelo Gaffo, Jasvinder Singh, Eric E. Kelley, David A. Calhoun, Louis J. Dell'Italia

Summary: Racial differences in XO activity and mtDNA DAMPs were observed in Black and White adults with resistant hypertension. Black resistant hypertension patients had higher XO activity, worse diastolic dysfunction, and greater mtDNA DAMPs than White patients. Urinary sodium excretion was correlated with left ventricular function in Black patients. These findings highlight the importance of further investigating the role of XO and mtDNA DAMPs in cardiac remodeling and heart failure in Black adults with resistant hypertension.

HYPERTENSION (2022)

Article Rheumatology

Patient Empowerment Among Adults With Arthritis: The Case for Emotional Support

Kathleen L. Carluzzo, Erin M. Knight, Karen E. Schifferdecker, Rebecca L. Butcher, Guy S. Eakin, Julie A. Eller, Jasvinder A. Singh

Summary: This study aimed to identify differences in patient empowerment among arthritis patients and found that factors such as gender, age, education, income, arthritis type, emotional support, and physical function are associated with patient empowerment. Among these factors, emotional support has the most significant impact on patient empowerment.

JOURNAL OF RHEUMATOLOGY (2022)

Editorial Material Medicine, General & Internal

Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future

Jasvinder A. Singh

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Editorial Material Rheumatology

COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Michael Putman, Kevin Kennedy, Emily Sirotich, Jean W. Liew, Sebastian E. Sattui, Tarin T. Moni, Akpabio A. Akpabio, Deshire Alpizar-Rodriguez, Saskya Angevare, Richard P. Beesley, Francis Berenbaum, Inita Bulina, Yu Pei Eugenia Chock, Richard Conway, Ali Duarte-Garcia, Aman Dev Singh, Eimear Duff, Karen L. Durrant, Tamer A. Gheita, Catherine L. Hill, Richard Howard, Bimba F. Hoyer, Evelyn Hsieh, Lina el Kibbi, Adam Kilian, Alfred H. J. Kim, David F. L. Liew, Chieh Lo, Elsa F. Mateus, Bruce Miller, Serena Mingolla, Michal Nudel, Jasvinder A. Singh, Namrata Singh, Manuel F. Ugarte-Gil, John Wallace, Kristen J. Young, Erick Adrian Zamora-Tehozol, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro M. Machado, Philip C. Robinson, Paul Sufka, Zachary S. Wallace, Jinoos Yazdany, Carly Harrison, Maggie J. Larche, Mitchell Levine, Gary Foster, Lehana Thabane, Jonathan S. Hausmann, Jeffrey A. Sparks, Julia F. Simard

LANCET RHEUMATOLOGY (2022)

Article Rheumatology

Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials

Lisa K. Stamp, Christopher Frampton, Melanie B. Morillon, William J. Taylor, Nicola Dalbeth, Jasvinder A. Singh, Michael Doherty, Weiya Zhang, Helen Richardson, Aye Sarmanova, Robin Christensen

Summary: Analyzing data from two randomized trials on urate-lowering therapies, this study found that achieving an average serum urate concentration less than 6 mg/dL is associated with reduced gout flares in the subsequent 12 months, supporting the use of a treat-to-target serum urate approach in gout management.

LANCET RHEUMATOLOGY (2022)

Article Rheumatology

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative

Kathleen M. Andersen, Benjamin A. Bates, Emaan S. Rashidi, Amy L. Olex, Roslyn B. Mannon, Rena C. Patel, Jasvinder Singh, Jing Sun, Paul G. Auwaerter, Derek K. Ng, Jodi B. Segal, Brian T. Garibaldi, Hemalkumar B. Mehta, G. Caleb Alexander

Summary: This study found that the use of immunosuppressive medications in hospitalized COVID-19 patients was associated with a reduced risk of invasive ventilation, but overall no association with in-hospital death. Some medication classes may be associated with an increased risk of death for specific diseases, such as rituximab for rheumatological disease and cancer. Careful medication selection is needed for COVID-19 patients with long-term immunosuppression.

LANCET RHEUMATOLOGY (2022)

Article Rheumatology

Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the US National COVID Cohort Collaborative (N3C)

Namrata Singh, Vithal Madhira, Chen Hu, Amy L. Olex, Timothy Bergquist, Kathryn C. Fitzgerald, Jared D. Huling, Rena C. Patel, Jasvinder A. Singh

Summary: This study assessed the association between rituximab (RTX) use and COVID-19 outcomes in rheumatoid arthritis (RA) patients. The results showed that compared to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), RTX use was associated with increased odds of COVID-19-related hospitalization, ICU admission, and invasive ventilation. These findings can provide guidance for decision-makers, healthcare providers, and patients during the COVID-19 pandemic.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Review Oncology

The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases

Jasvinder A. A. Singh

Summary: Janus kinase inhibitor (JAKi) medications are highly effective oral drugs for treating rheumatic diseases. They have similar safety concerns to biologic therapies but also have distinct differences. Recent data comparing JAKi with tumor necrosis factor inhibitors (TNFi) led to new warnings about cardiovascular and cancer risks by the FDA. This review summarizes the current published data on the safety of JAKi in rheumatic diseases, including risk differences between agents and indications.

BIODRUGS (2023)

Meeting Abstract Rheumatology

Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews

Simon Helfgott, Kent Kwas Huston, Jasvinder Singh, Nehad Soloman, Jeremy Broestl, Kimmi Cox, Kelsey Milligan, Colin Edgerton

ARTHRITIS & RHEUMATOLOGY (2022)

Meeting Abstract Rheumatology

Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis

Kent Kwas Huston, Christopher Adams, Simon Helfgott, Jasvinder Singh, Nehad Soloman, Dan Persons, Scott Milligan, Colin Edgerton

ARTHRITIS & RHEUMATOLOGY (2022)

No Data Available